A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers

BACKGROUND: Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, is approved in combination with endocrine therapy or as monotherapy for hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2−) advanced breast cancer outside of China. OBJECTIVE: To evaluate th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Target Oncol
Autori principali: Zhang, Jian, Yang, Nong, Ji, Dongmei, Shen, Weina, Li, Wenhua, Han, Rubing, Wang, Ning, Tao, Haoxun, Chapman, Sonya C., Sykes, Amanda K., Zhang, Wanli, Hu, Xichun
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2021
Soggetti:
Original Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7935732/
https://ncbi.nlm.nih.gov/pubmed/33492568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-020-00789-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi